


Supplementary Figure 1 – Overview of the SLTC pathway



Variable	N	VTA (n=19)	N	FTFA (n=30)	P value
Age	19	57.0 (49.0-60.0)	30	61.5 (56.8-64.3)	0.05
Sex (male)	19	13 (68.4%)	30	18 (60.0%)	0.76
Current/Ex-smoker	19	8 (42.1%)	29	14 (48.3%)	0.77
ARLD	19	9 (47.4%)	30	9 (30.0%)	0.24
NAFLD	19	2 (10.5%)	30	5 (16.7%)	0.69
Autoimmune liver diseases (PBC/PSC/AIH)	19	6 (31.6%)	30	13 (43.3%)	0.55
Redo transplantation	19	1 (5.3%)	30	0 (0.0%)	0.39
HCC	19	0 (0.0%)	30	2 (6.7%)	0.52
UKELD	19	54.5 (5.7)	30	54.1 (6.0)	0.81
MELD	19	12 (10.3-16.8)	30	10 (6.8-13.5)	0.10
CP score	19	8.6 (2.7)	30	7.8 (1.6)	0.24
Time from referral to completion of assessment	19	62 (48.0-125.0)	28	42 (21.0-54.5)	0.01*
Patient listed for transplant	19	18 (94.7%)	30	26 (86.7%)	0.64

Supplementary Table 1. Table demonstrating a comparison of demographic, clinical and prognostic scores between patients assessed via VTA and FTFA.

Results from *t* tests are displayed as mean (SD). Results from Mann Whitney *U* tests are displayed as median (IQR). Results from Fisher's exact tests are presented as

number (%). Statistical significance was determined by a p value <0.05 and signified by *.